Therapy-enhancing glucan

• US 20060188506A1
• Filed: 07/16/2004
• Published: 08/24/2006
• Est. Priority Date: 07/16/2003
• Status: Active Grant

• Current Assignee: Biotec BetaGlucans AS (Lallemand Inc.), Sloan-Kettering Institute For Cancer Research (Memorial Sloan-Kettering Cancer Center)
• Original Assignee: Sloan-Kettering Institute For Cancer Research (Memorial Sloan-Kettering Cancer Center)
• Inventors: Cheung, Nai-Kong V.
• Granted Patent: US 7,704,973 B2
• Time in Patent Office: Days
• US Class Current: 424/155.100
• CPC Class Codes: A61K 2039/55583 Polysaccharides
• CPC Class Codes: A61K 2300/00 Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
• CPC Class Codes: A61K 31/715 Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
• CPC Class Codes: A61K 31/716 Glucans
• CPC Class Codes: A61K 31/739 Lipopolysaccharides
• CPC Class Codes: A61K 39/39 characterised by the immunostimulating additives, e.g. chemical adjuvants
• CPC Class Codes: A61K 39/39541 against normal tissues, cells
• CPC Class Codes: A61K 39/39558 against tumor tissues, cells, antigens
• CPC Class Codes: A61K 39/44 Antibodies bound to carriers
• CPC Class Codes: A61K 47/36 Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
• CPC Class Codes: A61P 35/00 Antineoplastic agents
• CPC Class Codes: A61P 37/04 Immunostimulants
• CPC Class Codes: A61P 43/00 Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
• CPC Class Codes: C08B 37/0024 beta-D-Glucans; (beta-1,3)-D-Glucans, e.g. paramylon, coriolan, sclerotan, pachyman, callose, scleroglucan, schizophyllan, laminaran, lentinan or curdlan; (beta-1,6)-D-Glucans, e.g. pustulan; (beta-1,4)-D-Glucans; (beta-1,3)(beta-1,4)-D-Glucans, e.g. lichenan; Derivatives thereof

Abstract

This invention provides a method for introducing substances into cells comprising contacting a composition comprising orally administered beta-glucan with said cells. This invention also provides a method for introducing substances into a subject comprising administering to the subject an effective amount of the above compositions. The substance. which could be delivered orally includes but is not limited to peptides, proteins, RNAs, DNAs, chemotherapeutic agents, biologically active agents, plasmids, and other small molecules and compounds. Finally, this invention provides a composition comprising orally administered beta-glucan capable of enhancing efficacy of IgM and different uses of the said composition.

Claims

1. A composition for oral uptake of substance comprising an appropriate amount of carbohydrates.

3. The composition of any one of claims 1 or 2, wherein the carbohydrate is glucan.

4. The composition of claim 3, wherein the glucan contains 1,3-1,6 or 1,3-1,4 mixed linkages or a mixture of both 1,3-1,6 and 1,3-1,4 mixed linkages.

5. The composition of claim 3, wherein the glucan enhances the efficacy of chemotherapeutic agents or anti-cancer antibodies.

6. The composition of claim 3, wherein the glucan is derived from grass, plants, mushroom, yeast, barley, fungi, wheat or seaweed.

7. The composition of claim 3, wherein the glucan is of high molecular weight.

8. The composition of claim 3, wherein the substance is a peptide, protein, RNA, DNA or plasmid.

9. The composition of claim 3, wherein the substance is a chemotherapeutic agent.

2. A composition for the oral delivery of one or more substances comprising an effective amount of an orally administered beta-glucan and one or more chemotherapeutic agents.

10. A composition comprising an effective amount of orally administered (1→

3),(1→

6) or (1→

3),(1→

4) beta-glucan capable of enhancing efficacy of IgM antibodies.

11. The composition of claim 10, wherein the antibody is an antibody against cancer.

12. The composition of claim 11, wherein the antibody is a tumor-binding antibody.

13. The composition of claim 12, wherein the antibody is capable of activating complement.